Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Expansion in clinical trial eligibility requested by ASCO

Friends of Cancer and ASCO letter to the FDA

Key clinical point: ASCO and Friends of Cancer have submitted draft recommendations to the FDA for expanding cancer clinical trial participation.

Major finding: The organizations recommend addressing minimum age requirements, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.

Data source: Draft guidance produced by ASCO and Friends of Cancer Research and submitted to the FDA.

Disclosures: Individual members of the working groups were not listed and conflicts of interest were not disclosed.

Read the article.


Friends of Cancer and ASCO letter to the FDA.

This Week's Must Reads

Study examines rehabilitative palliative care in cancer, Nottelmann L et al. 2018 Palliative and Supportive Care in Oncology Symposium Abstract 75

HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901

Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774

RNA editing contributes to myeloma pathogenesis, Teoh PJ et al. Blood. 2018;132(12):1304-17

Transcription factor networks in AML, Assi SA et al. Nat Genet. 2018 Nov 12. doi: 10.1038/s41588-018-0270-1

Must Reads in Business of Medicine

For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.